Short answer: Ozempic, Mounjaro and the other drugs in their class may slightly raise the risk of NAION, a rare eye condition that causes sudden, painless vision loss in one eye. On November 9, 2026, the FDA said the risk is "potential" and rare, and told every maker to add it to the Warnings and Precautions section of the label (FDA Drug Safety Communication, Nov 9, 2026). In the FDA's pooled look at 126 clinical trials, NAION happened at 6.4 cases per 100,000 person-years on these drugs versus 3.8 on comparators. People with diabetes, older adults and people with heart and blood vessel risk factors start out at higher risk. If your vision suddenly changes in one eye, get checked the same day.
This article explains what NAION is, what the FDA and Europe's regulator found, what the research does and does not show, and who seems to be more at risk. It is for education, not medical advice.
What NAION is
NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain words: the front part of the optic nerve, the cable that carries what your eye sees to your brain, does not get enough blood flow and gets damaged. The FDA describes it as acute, painless, decreased vision in one eye that can be permanent (FDA).
The symptoms the FDA lists are:
- Sudden, painless vision loss in one eye, often noticed on waking
- Blurred or missing parts of your vision, such as blind spots or tunnel vision
- Colors that look washed out or distorted
- Less sharp central vision, like a blurry or hazy spot
NAION happens without these drugs too. The FDA cites a background rate of 2.3 to 10.2 cases per 100,000 people per year in adults over 50. Once it has happened in one eye, the other eye is at higher risk.
What the FDA announced in November 2026
The FDA's review started after a 2024 study from Massachusetts Eye and Ear (more on it below). The agency then looked at clinical trials, animal studies, adverse event reports and real-world records. Its main findings (FDA Drug Safety Communication):
- Clinical trials: 126 randomized trials with 134,253 patients. There were 15 probable NAION cases in total: 10 on the drugs, 5 on placebo, none on other diabetes drugs. That works out to 6.4 versus 3.8 cases per 100,000 person-years.
- Real-world records: In the FDA's Sentinel study of adults with type 2 diabetes who started a drug from this class, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024, NAION rates were 26 to 32 per 100,000 person-years in every group. Versus SGLT-2 inhibitors there was no statistically significant difference (hazard ratio 1.19, 95% CI 0.91 to 1.54). Versus DPP-4 inhibitors, risk was higher (hazard ratio 1.43, 95% CI 1.02 to 2.01).
- Animal studies: no mechanism was found that would explain how these drugs could cause NAION.
- Case reports: NAION has been reported with every drug in the class on the market. The FDA says these reports are hard to read because NAION risk factors overlap with the conditions these drugs treat.
The FDA's list covers Ozempic, Rybelsus and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), Victoza, Saxenda and Xultophy (liraglutide), Trulicity (dulaglutide), Soliqua (lixisenatide), Foundayo (orforglipron) and generic exenatide. So this is not only an Ozempic question.
When we checked the current labels on DailyMed on November 22, 2026, the posted versions of Ozempic, Wegovy, Mounjaro and Zepbound did not mention NAION yet. The new wording should appear as each maker updates its label. For a fuller breakdown of the announcement, see Dose Track's NAION eye warning explainer.
Europe reached a similar answer first
In June 2025, the European Medicines Agency's safety committee (PRAC) concluded that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people (EMA, June 6, 2025). The EMA said large studies in adults with type 2 diabetes point to roughly a two-fold higher risk, which it put at about one extra case per 10,000 person-years. Its advice: contact your doctor without delay if you have sudden vision loss or fast-worsening eyesight, and stop semaglutide if NAION is confirmed.
What the research shows, study by study
The numbers in headlines vary a lot because the studies are very different. Here are the main ones, all observational unless noted, which means they show links, not proof of cause.
- Hathaway 2024 (the study that started it): 16,827 patients seen by neuro-ophthalmologists at one Boston hospital. People prescribed semaglutide had higher NAION risk: hazard ratio 4.28 in type 2 diabetes and 7.64 in overweight or obesity. The authors said future study is needed to assess cause (PubMed 38958939). Because everyone in it was already being seen at an eye specialty clinic, its numbers may not match the general public.
- Denmark and Norway 2025: about 61,000 people with type 2 diabetes starting semaglutide, compared with people starting SGLT-2 inhibitors. Risk was higher (pooled hazard ratio 2.81), but the absolute rate stayed low: about 2 to 3 cases per 10,000 person-years on semaglutide (PubMed 40098249).
- OHDSI network 2025: 37.1 million people with type 2 diabetes, including 810,390 new semaglutide users, across 14 US databases. It found a modest increase, smaller than first reported, with an incidence of 14.5 per 100,000 person-years on semaglutide (PubMed 39976940).
- Semaglutide or tirzepatide 2025: a US records study of people with type 2 diabetes found NAION in 0.04% of the semaglutide or tirzepatide group versus 0.02% of matched people on other diabetes drugs over 2 years (hazard ratio 1.76) (PubMed 40788646). This is one of the few studies that includes Mounjaro's ingredient.
- Trial reviews: A 2026 meta-analysis split the data by why people took semaglutide. It found a signal only in observational studies of people with diabetes (hazard ratio 1.85), which the randomized trials did not confirm (PubMed 41475544). A 2026 pooled analysis of Novo Nordisk's own placebo-controlled trials, written partly by company staff, found 3 confirmed cases on drug and 5 on placebo (PubMed 42049287).
In 2026, the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology summed it up this way: many studies report a small possible increase, some find none, the overall risk stays low, and the decision to start, continue or stop should be shared between each patient and their care team (PubMed 42132708).
Who is more at risk?
No study has pinned down exactly who will get NAION on these drugs. What we do know is who starts out at higher risk, based on the FDA's list and the study groups above:
- People with a past NAION. The FDA notes a higher risk of it coming back, and of it affecting the other eye.
- People with type 2 diabetes. Most of the studies that found a signal were in this group, and diabetes itself is a NAION risk factor.
- Adults over 50. The background rates the FDA cites are for this age group.
- People with smoking, high blood pressure, sleep apnea, anemia or kidney disease. These are the risk factors the FDA lists.
Many people who take Ozempic, Wegovy, Mounjaro or Zepbound have several of these at once. That overlap is a big part of why the link has been so hard to sort out.
NAION is not the same as the retinopathy warning
The Ozempic label already has a separate eye warning about diabetic retinopathy complications, which is damage to the retina, not the optic nerve. In a 2-year trial in people with type 2 diabetes and high heart risk, these complications happened in 3.0% on Ozempic versus 1.8% on placebo. The gap was bigger in people who already had retinopathy (8.2% vs 5.2%) than in those who did not (0.7% vs 0.4%) (Ozempic label, section 5.3). The label says fast improvement in blood sugar has been linked to temporary worsening of retinopathy, and that people with a history of it should be monitored. The Mounjaro and Zepbound labels carry the same kind of warning (sections 5.7 and 5.8). The Ozempic Medication Guide also tells patients to report any change in vision.
What to do with this
- Know the signs. Sudden, painless vision loss or blurring in one eye, missing patches, or colors that look off. The FDA says to contact a health care professional right away.
- Do not stop on your own. The FDA does not tell people without symptoms to stop. If NAION is diagnosed, talk with your clinician about whether to continue.
- Mention your history. Tell your prescriber about past NAION, retinopathy, sleep apnea or other risk factors before starting.
- Keep a record. If something changes, your eye doctor will ask which drug you take, since when, and at what dose. A simple dose log, like the one in Dose Track's GLP-1 tracker, makes that answer quick. Our Ozempic page covers the label basics.
- Report it. Side effects can be reported to the FDA through MedWatch.
Sources
- FDA Drug Safety Communication, November 9, 2026: potential increased risk of NAION with GLP-1 receptor agonists (fda.gov)
- EMA PRAC, June 6, 2025: NAION a very rare side effect of semaglutide (ema.europa.eu)
- Ozempic, Wegovy, Mounjaro and Zepbound prescribing information, DailyMed, checked November 22, 2026
- Hathaway JT et al. JAMA Ophthalmol 2024. PMID 38958939
- Simonsen E et al. Diabetes Obes Metab 2025. PMID 40098249
- Cai CX et al. JAMA Ophthalmol 2025. PMID 39976940
- Wang L et al. JAMA Netw Open 2025. PMID 40788646
- Liu Z et al. Ophthalmology 2026. PMID 41475544
- Vilsbøll T et al. Br J Ophthalmol 2026. PMID 42049287
- DeParis SW et al. Ophthalmology 2026 (NANOS and AAO consensus). PMID 42132708
This article is for education only and is not medical advice. Talk with your own clinician about your eyes and your medicines.

